Cel-Sci (CVM) vs Quince Therapeutics (QNCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cel-Sci (CVM) has outperformed Quince Therapeutics (QNCX) over the past year, losing 80.6% versus a loss of 92.4%. Over five years, CVM leads with a -99.4% price change compared with -99.8% for QNCX. Cel-Sci is the larger company by market cap ($34.3 million vs $29.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CVM | QNCX |
|---|---|---|
| Share price | $1.95 | $29.36 |
| Market cap | $34.30M | $29.86M |
| 1-day change | -8.45% | +9.88% |
| YTD return | -62.93% | -95.62% |
| 1-year return | -80.56% | -92.35% |
| 5-year return | -99.38% | -99.77% |
| EPS (TTM) | $-1.69 | $-214.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.39 | $910.00 |
| 52-week low | $0.89 | $15.10 |
| Distance from 52-week high | -81.23% | -96.77% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +541.03% | +156.91% |
| Average volume | 241.50K | 28.83K |
| Shares outstanding | 17.59M | 1.02M |
| Employees | — | 38 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CVM has outperformed QNCX by 11.8 percentage points over the past year.
About Cel-Sci
CVM stock →CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.
Healthcare · Biotechnology
About Quince Therapeutics
QNCX stock →Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Healthcare · Biotechnology · 38 employees
CVM vs QNCX FAQ
Which is bigger, Cel-Sci or Quince Therapeutics?
Cel-Sci (CVM) is larger, with a market capitalization of $34.30M compared with $29.86M for Quince Therapeutics (QNCX).
Which stock has performed better over the past year, CVM or QNCX?
CVM returned -80.56% over the past 12 months, compared with -92.35% for QNCX (price return, excluding dividends). Past performance does not predict future results.
Are Cel-Sci and Quince Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.